Valuation Gedeon Richter LUXEMBOURG S.E.

Stocks

CHWGR

US3684672054

Pharmaceuticals

End-of-day quote LUXEMBOURG S.E. 22/10/2026			5-day change	1st Jan Change
39.20 ^USD	+0.51%		0.00%	+29.80%

14/10	Gedeon Richter Plc. Receives Fda Submission Acceptance of New Drug Application for Fylrevy® in the U.S	CI
18/09	EU Medicines Agency Panel Issues Positive Opinion on Gedeon Richter's Arthritis Drug	MT

Company Valuation: Gedeon Richter

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	16,19,625	15,42,290	16,27,029	18,93,161	17,99,226	24,02,084	-	-
Change	-	-4.77%	5.49%	16.36%	-4.96%	33.51%	-	-
Enterprise Value (EV) ¹	15,59,769	13,95,557	15,46,536	17,82,343	15,88,618	21,39,608	19,92,072	18,65,104
Change	-	-10.53%	10.82%	15.25%	-10.87%	34.68%	-6.9%	-6.37%
P/E	11.6x	9.94x	10.2x	7.96x	7.76x	9.69x	8.29x	7.67x
PBR	1.78x	1.47x	1.44x	1.49x	1.31x	1.6x	1.45x	1.31x
PEG	-	0.9x	3.41x	0.2x	-2.82x	1.4x	0.5x	0.95x
Capitalization / Revenue	2.57x	1.92x	2.02x	2.21x	1.94x	2.52x	2.35x	2.2x
EV / Revenue	2.47x	1.74x	1.92x	2.08x	1.71x	2.25x	1.95x	1.71x
EV / EBITDA	8.86x	7.1x	6.43x	5.74x	4.5x	5.82x	5.03x	4.39x
EV / EBIT	11.5x	9.09x	8.15x	6.82x	5.42x	7.08x	5.98x	5.19x
EV / FCF	-460x	12.3x	17.9x	8.26x	7.56x	9.47x	8.69x	7.54x
FCF Yield	-0.22%	8.12%	5.6%	12.1%	13.2%	10.6%	11.5%	13.3%
Dividend per Share ²	225	390	-	-	-	603.6	677	738.7
Rate of return	2.58%	4.7%	-	-	-	4.58%	5.14%	5.61%
EPS ²	751	835	860	1,307	1,271	1,359	1,589	1,718
Distribution rate	30%	46.7%	-	-	-	44.4%	42.6%	43%
Net sales ¹	6,30,595	8,02,755	8,05,158	8,57,545	9,28,962	9,51,368	10,20,834	10,93,689
EBITDA ¹	1,76,123	1,96,480	2,40,625	3,10,678	3,53,314	3,67,576	3,96,366	4,25,015
EBIT ¹	1,35,832	1,53,555	1,89,817	2,61,157	2,92,851	3,02,220	3,32,887	3,59,032
Net income ¹	1,39,626	1,55,581	1,58,850	2,39,244	2,32,335	2,54,304	2,90,549	3,14,929
Net Debt ¹	-59,856	-1,46,733	-80,493	-1,10,818	-2,10,608	-2,62,476	-4,10,012	-5,36,980
Reference price ²	8,725.00	8,300.00	8,750.00	10,400.00	9,865.00	13,170.00	13,170.00	13,170.00
Nbr of stocks (in thousands)	1,85,630	1,85,818	1,85,946	1,82,035	1,82,385	1,82,391	-	-
Announcement Date	02/03/22	28/02/23	29/02/24	07/04/25	27/02/26	-	-	-

¹HUF in Million²HUF

Estimates

P/E, Detailed evolution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	36.67x	13.07x	27.74x	0.54%	1,13300Cr
JOHNSON & JOHNSON	37.73x	6.36x	17.89x	2.07%	62TCr
ABBVIE INC.	36.35x	8.36x	17.26x	2.41%	50TCr
ROCHE HOLDING AG	21.21x	5.12x	12.74x	2.55%	38TCr
MERCK & CO., INC.	109.25x	6.09x	26.14x	2.27%	37TCr
NOVARTIS AG	21.57x	5.62x	13.82x	2.84%	29TCr
ASTRAZENECA PLC	22.08x	4.46x	12.77x	1.98%	26TCr
AMGEN INC.	27.83x	7.14x	12.79x	2.3%	24TCr
GILEAD SCIENCES, INC.	-44.76x	6.88x	26.67x	2.15%	19TCr
Average	29.77x	7.01x	18.64x	2.12%	44.31TCr
Weighted average by Cap.	35.57x	8.27x	20.36x	1.81%